scholarly journals Effect of COVID 19 on Lower Urinary Track Symptoms in Patients With Benign Prostatic Hyperplasia

2021 ◽  
Author(s):  
Ahmed Elaimeri ◽  
Amr A Alemairy
Keyword(s):  
International Prostate Symptom Score ◽  
Prostatic Hyperplasia ◽  
Paired Sample ◽  
Appropriate Treatment ◽  
Male Patients ◽  
The Mean ◽  
Over 40 Years ◽  
Pcr Test ◽  
Morbid Conditions ◽  
Lower Urinary

Abstract Background: Lower Urinary Track Symptoms (LUTS) in patients with BPH could be assessed by the International Prostate Symptom Score (IPSS). Studies find that COVID-19 can be detected in urine samples, although unreliably, this suggest the need to investigate whether the virus has effect on the urinary track especially those who are with pre-morbid conditions such as BPH. Hence the study aims to assess the effect of COVID-19 on the LUTS measured objectively by the IPSS on patients with BPH.Methods: 85 male patients over 40 years of age already diagnosed with BPH were included in the study. Any patient who recovered from a confirmed oropharyngeal swap PCR test was reassessed using I-PSS. Post-COVID19 IPSS surveys were compared to pre-COVID19 ones.Results: Out of 85 subjects, 39 (45.9%) were mild before COVID-19 compared to 19 (22.4%) after the infection. 46 subjects (54.1%) were moderate before COVID-19, whereas, 66 (77.6%) became moderate after the infection, (P < 0.001). The mean IPSS score of patients after they receive the appropriate treatment was found to be (8.1), while the mean score after COVID-19 infection was found to be (9.8). (P < 0.001) using paired sample t test.Conclusions: COVID-19 is associated with higher I-PSS score in patients with BPH, and more objective assessments are needed for further investigation.

scholarly journals A comparative clinical evaluation of outcome of medical and surgical management of symptoms due to benign prostatic hyperplasia

2020 ◽  
Vol 7 (9) ◽  
pp. 3032
Author(s):  
Bhushan Kumar Gnana ◽  
Sanjeeva Rao Matlapudi
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Surgical Management ◽  
Benign Neoplasm ◽  
Prostatic Hyperplasia ◽  
Single Drug ◽  
Urinary Tract Symptoms ◽  
Rectal Digital Examination ◽  
The Mean ◽  
Lower Urinary

Background: Benign hypertrophy of prostate is common disorder and benign neoplasm of man above 50 years of age. Around 30% patients with benign hypertrophy of prostate lower urinary tract symptoms (LUTS) but all symptoms may not be due to benign hypertrophy of prostate (BHP). Present study has been designed for comparative evaluation of the outcome of medical and surgical management of symptoms, due to benign prostatic hyperplasia by using IPSS (international prostate score) and quality of life score as tool.Methods: In present study patients with LUTS, clinically diagnosed by per rectal digital examination and transrectal ultrasonographically confirmed cases of enlargement of prostate are enrolled for this study. Patients enrolled were divided equally in three groups.Results: After six month the mean IPSS score in silodosin (Sd) group was 6.55±0.86 and in Sd+Dutasteride (Dt) group it was 5.09±1.12. After six months mean IPSS score in Sd+Dt group was 5.09±1.12 and in TURP group it was 2.44±0.59.Conclusions:  Single drug treatment with silodosin is associated with slow and less improvement in IPSS score in comparison with silodosin and dutasteride. But the response to TURP was better and faster than medical management.

scholarly journals PROSTATIC HYPERPLASIA;

2017 ◽  
Vol 24 (10) ◽  
pp. 1560-1565
Author(s):  
Muhammad Sheraz Javed ◽  
Safdar Hassan Javed
Keyword(s):  
Prostatic Hyperplasia ◽  
Significant Response ◽  
Age Group ◽  
Urinary Tract Symptoms ◽  
Prostate Size ◽  
Group A ◽  
Male Patients ◽  
Comparative Results ◽  
Group B ◽  
Lower Urinary

Lower Urinary Tract Symptoms. Alpha-1 adrenoceptor antagonists are mostfrequently prescribed medical management for LUTS and among these tamsulosin andterazosin are the most common. Objectives: To access comparison of efficacy of tamsulosinand terazosin for management of LUTS due to prostatic hyperplasia in terms of InternationalProstate Symptom Score (IPSS). Place and duration: Study being conducted at Departmentof Urology and Kidney Transplantation, Allied Hospital, Faisalabad for period of 24 months from01-07-2014 to 30-06-2016. Methodology: 659 male patients enrolled in study and randomlyassigned to Group A (Patients being administered with tamsulosin) and Group B (Patients beingadministered with terazosin) and improvement in IPSS monitored over period of two weeks.Results: 659 patients enrolled with mean age+sd as 61.9+10.2 years. Group A includes 330patients while Group B include 329 patients. Among Group A, 250 patients showed significantimprovement in IPSS while in Group B, 215 patients showed significant response to medicalmanagement in terms of IPSS and both groups showed statistically comparative response.Statistical response of management also determined in terms of variables of IPSS severity,prostatic size and age of patient and found that efficacy of the two groups were statisticallycomparable for patients with mild IPSS while in patients with moderate IPSS has response totreatment with tamsulosin but no statistical association of efficacy for treatment with terazosin.No statistical response was found for improvement in symptoms in cases with severe IPSS ineither groups. When response monitored in terms of prostate size in both groups, it was foundthat both groups have statistical response when prostate size is less than 35 grams, between35-55 grams but in case when prostate size was more than 55 grams, no statistical responsewas found with group B patients. When response was measured in terms of variable of age,results were consistent with the fact that statistically significant response of efficacy was foundin either groups for age group 45-55 years and 56-65 years but no statistical response wasfound for Group B when considered for age group more than 65 years. Conclusion: Based onresults it is concluded that both tamsulosin and terazosin has got comparative results in overallresponse. However, tamsulosin has superiority in treatment when IPSS is moderate, prostatesize is more than 55 grams and age of patient is more than 65 years.

What Is the Interaction between Urine C-Reactive Protein, Prostatic Inflammation, and Doxazosin Treatment in Patients with Benign Prostatic Hyperplasia? A Pilot Study

2021 ◽  
pp. 1-5
Author(s):  
Ahmet Asfuroglu ◽  
Melih Balci ◽  
Yilmaz Aslan ◽  
Cagdas Senel ◽  
Ozer Guzel ◽  
...  
Keyword(s):  
International Prostate Symptom Score ◽  
Prostatic Hyperplasia ◽  
Urinary Flow ◽  
C Reactive Protein ◽  
Alpha Blocker ◽  
Reactive Protein ◽  
The Mean ◽  
Maximum Urinary Flow ◽  
First Admission

<b><i>Introduction:</i></b> It was aimed to show the relationship between benign prostatic hyperplasia and inflammation by measuring urinary C-reactive protein values before and after alpha-blocker treatment. <b><i>Methods:</i></b> A total of 71 patients with a total prostate-specific antigen &#x3c;3.5 ng/mL, International Prostate Symptom Score &#x3e;7, and maximum urinary flow rate &#x3c;15 mL/s were included in the study. Doxazosin 4 mg p.o. once daily was started orally as an alpha-blocker treatment. Serum and urine C-reactive protein values, International Prostate Symptom Score, maximum urinary flow rate, and the post-void residual volume of patients were recorded at the first admission and in the first month of alpha-blocker treatment. <b><i>Results:</i></b> The mean age of the patients was 59.2 ± 7.5 years. The mean serum C-reactive protein values of the patients at the first admission and follow-up were 2.62 ± 1.8 (range, 0–5) mg/L and 2.83 ± 1.6 (0–6) mg/L, respectively. The mean urine C-reactive protein values of the patients at the first admission and follow-up were 0.45 ± 0.11 (range, 0.28–0.99) mg/L and 0.14 ± 0.04 (range, 0.79–0.328) mg/L, respectively, which was statistically significantly different. In the subgroup analysis, the urine C-reactive protein level change was more prominent in severely symptomatic patients than in moderately symptomatic patients. <b><i>Conclusion:</i></b> Our results showed that C-reactive protein was detectable in urine, alpha-blocker treatment significantly reduced urine C-reactive protein levels, and the decrease was more prominent in severely symptomatic patients.

scholarly journals Correlation of prostate volume with severity of lower urinary tract symptoms as measured by international prostate symptoms score and maximum urine flow rate among patients with benign prostatic hyperplasia

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Mudi Awaisu ◽  
Muhammed Ahmed ◽  
Ahmad Tijjani Lawal ◽  
Abdullahi Sudi ◽  
Musliu Adetola Tolani ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Flow Rate ◽  
Lower Urinary Tract ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Urine Flow ◽  
Urine Flow Rate ◽  
Urinary Tract Symptoms ◽  
The Mean ◽  
Lower Urinary

Abstract Background The aim of the study is to find the correlation between the prostate volume and severity of lower urinary tract symptoms (LUTS) as measured by international prostate symptoms score and maximum urine flow rate among patients with benign prostatic hyperplasia (BPH). Methods The study was a prospective correlational study conducted between June 2016 and November 2017. A total of 290 patients who presented with LUTS suggestive of BPH and satisfied the inclusion criteria were consecutively recruited. Clinical evaluation including digital rectal examination of the prostate was done. Symptoms severity was assessed using the self-administered international prostate symptoms score (IPSS) questionnaire. Prostate volume was determined by transrectal ultrasound scan, and the urine flow rate was measured using uroflowmeter. Data were analyzed using SPSS version 20.0, and p value < 0.05 was taken to be statistically significant. Results The mean age of the patients was 64.22 ± 9.04 years with a range of 40 to 95 years. Most of the patients had moderate symptoms (55%) on IPSS with the mean IPSS value of 16.41 ± 7.43. The mean Qmax value was 16.55 ± 7.41 ml/s, and the median prostate volume (IQR) was 45.05 (35, 59). There was a positive significant correlation between prostate volume and IPSS (r = 0.179, p = 0.002) and a negative significant correlation between prostate volume and Qmax (r = − 0.176, p = 0.003). Conclusion This study showed a significant correlation between the prostate volume and IPSS, and also between prostate volume and maximum flow rate (Qmax).

Sign in / Sign up

Export Citation Format

Share Document